Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586446 | 1.00 | ERN1 (0.65) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL2652355 | 0.88 | ERN1 (0.69) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL2616938 | 0.86 | ERN1 (0.58) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL29051806 | 0.82 | TDP1 (0.55) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL14595562 | 0.82 | TDP1 (0.55) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL10889677 | 0.82 | ALDH1A1 (0.58) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL31098731 | 0.82 | ERN1 (0.67) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL12798324 | 0.82 | ERN1 (0.67) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL14429947 | 0.80 | ERN1 (0.56) | ERN1TDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL1800032 | 0.80 | ERN1 (0.65) | ERN1TDP1ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-19 | — | — | US | disclosed |
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-09-05 | — | — | US | disclosed |
| CN-117957218-A | Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins | 凯普托尔治疗学股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| EP-4347579-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2024-04-10 | — | — | EP | disclosed |
| EP-4271670-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | Captor Therapeutics S.A. (PL) | 2023-11-08 | — | — | EP | disclosed |
| CN-116917275-A | Novel CEREBLON-binding compounds and methods of use thereof | 凯普托尔治疗学股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2022253713-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022144416-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CAPTOR THERAPEUTICS S.A. (PL) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021014415-A2 | SMALL MOLECULE INHIBITORS OF ACETYL COENZYME A SYNTHETASE SHORT CHAIN 2 (ACSS2) | CURADEV PHARMA PVT. LTD. (IN) | 2021-01-28 | — | — | WO | disclosed |
| EP-0436653-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991005556-A1 | CAMPTOTHECIN ANALOGS AS POTENT INHIBITORS OF HUMAN COLORECTAL CANCER | RESEARCH TRIANGLE INSTITUTE (US) | 1991-05-02 | — | — | WO | disclosed |
| US-4981968-A | ENZYME INHIBITORS, ANTITUMOR | RESEARCH TRIANGLE INSTITUTE (US) | 1991-01-01 | — | — | US | disclosed |
| WO-1990003169-A1 | SYNTHESIS OF CAMPTOTHECIN AND ANALOGS THEREOF | RESEARCH TRIANGLE INSTITUTE (US) | 1990-04-05 | — | — | WO | disclosed |
| US-4894456-A | CYCLIZATION, ESTERIFICATION | RESEARCH TRIANGLE INSTITUTE (US) | 1990-01-16 | — | — | US | disclosed |
| US-4404201-A | N-/ /ALKANOYLAMINOALKANOYLAMINO OR AMINOALKANOYL AMINO/-DIHYDRO-OXO-3-QUINOLINYLCARBONYL/- DERIVATIVES | WARNER-LAMBERT COMPANY (US) | 1983-09-13 | — | — | US | disclosed |
| US-4382089-A | Antibacterial amide compounds, compositions thereof and methods of using them | WARNER-LAMBERT COMPANY (US) | 1983-05-03 | — | — | US | disclosed |
| US-4374138-A | PENICILLINS | WARNER-LAMBERT COMPANY (US) | 1983-02-15 | — | — | US | disclosed |
| US-4268510-A | DEMETHANIZATION, METABOLISM, RUMEN | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-05-19 | — | — | US | disclosed |
| EP-0010348-A1 | Heterocyclic trichloromethyl derivatives, process for their preparation and their use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294499-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | MCL1, MDM2, XIAP | ERN1 1126/4885TDP1 3302/4885ALDH1A1 956/4885 |
| US-20240307547-A1 | NOVEL COMPOUNDS WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | CRBN, CDR2, FABP7 | ERN1 4237/4885TDP1 4453/4885ALDH1A1 3123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.